MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4103/ijo.ijo_3330_25

Медицинская библиотека · Indian journal of ophthalmology · 2026

Biosimilars in diabetic macular edema: Promise, progress, and pitfalls.

Jain Vanaja, Dave Vivek P, Shettigar Manoj P, Hwang De-Kuang, Demirel Sibel

СтатьяОбзорПеревод в очереди

Аннотация

Diabetic macular edema (DME) is a common microvascular complication of diabetes and a major cause of vision impairment. Intravitreal vascular endothelial growth factor (VEGF) inhibitors remain the gold standard for its management. However, the high cost and limited accessibility of reference anti-VEGF agents have driven growing interest in biosimilars-biologic therapies designed to match the efficacy, safety, and immunogenicity of their reference products. Following the expiration of patents for agents such as aflibercept and ranibizumab, several biosimilars have been developed, approved, and introduced into clinical practice. Evidence from real-world studies-including RE-ENACT2 (REal-life assessmENt of safety And effeCTiveness of Razumab) and REAR-RD2 (REal-world observational study to evaluate the risk factors in the management of REtinal Diseases-2)-as well as randomized clinical trials such as INSIGHT and CT-P42 has demonstrated clinical equivalence between these biosimilars and their reference anti-VEGF counterparts in the treatment of DME. This article provides an updated overview of the current evidence base, recent advances in regulatory pathways, and ongoing challenges in integrating biosimilars into routine DME management.

Для цитирования: Jain Vanaja, Dave Vivek P, Shettigar Manoj P, Hwang De-Kuang, Demirel Sibel. Biosimilars in diabetic macular edema: Promise, progress, and pitfalls.. Indian journal of ophthalmology. 2026. DOI: 10.4103/ijo.ijo_3330_25.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.